Paper 80 - A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)

Author(s)

• 

  Brian A. Van Tine, MD, PhD

  Professor of Medicine
  Washington University in St. Louis
  Saint Louis, Missouri, United States

  Slides

Co-Author(s)

• JB

  Jean-Yves Blay, MD, PhD

  Centre Léon Bérard
  Lyon, Rhone-Alpes, France
• GS

  Gary K. Schwartz, MD

  Professor
  Case Comprehensive Cancer Center
  Cleveland, Ohio, United States
• JB

  John D. Baird, N/A (he/him/his)

  CoS
  PTC Therapeutics, Inc.
  Warren, New Jersey, United States
• DD

  Dhiren D'Silva, N/A (he/him/his)

  VP Commercial Excellence
  PTC Therapeutics, Inc.
  Warren, New Jersey, United States
• JF

  John Finnefrock, PharmD

  Manager, Commercial Excellence
  PTC Therapeutics, Inc.
  Conroe, Texas, United States
• KO

  Kylie O'Keefe, N/A

  Chief Commercial Officer
  PTC Therapeutics, Inc.
  Warren, New Jersey, United States
• MR

  Mark Rance, N/A

  PTC Therapeutics, Inc.
  Warren, New Jersey, United States
• MW

  Marla Weetall, N/A

  PTC Therapeutics, Inc.
  Warren, New Jersey, United States
• 

  Robin L. Jones, BSc, MB BS, MRCP, MD

  Professor
  Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
  London, England, United Kingdom